FDA clears C2N Alzheimer's blood test for symptomatic adults as young as 40

The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 who show potential cognitive symptoms of Alzheimer's disease, according to the source. The test measures plasma amyloid and tau proteins by mass spectrometry and scores results as negative, likely positive, or positive. A cited clinical validation study of 1,142 symptomatic adults reported that the test identified 97.6% of positive biomarkers. The source says the test is not intended for general health screening.